NeuroSense shares surge 11.76% premarket after U.S. patent grant for Alzheimer's treatment and favorable phase 2 study results.

NeuroSense Therapeutics (NASDAQ: NRSN) surged 11.76% in premarket trading following the announcement that the U.S. Patent and Trademark Office granted a key patent for its Alzheimer’s disease treatment. The patent, covering the PrimeC combination therapy, extends intellectual property protection through 2043, reinforcing the company’s long-term commercialization prospects. Additionally, the firm reported favorable safety and tolerability results from its proof-of-concept Alzheimer’s study (RoAD), with clinical and biomarker data expected in Q1 2026. These developments highlight regulatory and clinical progress for the biotech firm, bolstering investor confidence in its pipeline for neurodegenerative diseases.